U.S. Securities and Exchange Commission
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): November 21, 2002
-----------------
HUAYANG INTERNATIONAL HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
Nevada 000-30173 58-1667944
(State or other) (Commission (I.R.S. Employer
jurisdiction File Number) Identification Number)
of incorporation
386 Qing Nian Avenue, Shenyang, China 110003
(Address of principal executive offices) (Zip code)
011 (86)(24) 2318-0688
(Issuer's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Item 5. Other Events and Regulation FD Disclosure
Jiahe Medicine Group ("Jiahe"), which Huayang International Holdings,
Inc. ("Company") acquired in September 2002 subject to certain contingencies,
has notified the Company that Jiahe has received the manufacturing permit
for Ezhen Jiaonang, a Chinese medicine primarily used for women's diseases
related to menopause. The permit became effective on October 25, 2002.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this registration statement to be
signed on its behalf by the undersigned, thereunto duly authorized.
Huayang International Holdings, Inc.
Date: November 21, 2002 /s/ Gao WanJun
-----------------
Name: Gao WanJun
Title: President and Chief
Executive Officer